公开(公告)号：US20220213092A1

公开(公告)日：2022-07-07

申请号：US17552396

申请日：2021-12-16

Applicant: AbbVie Inc.

Inventor： David A. DeGoey ,  Felix DeAnda, Jr. ,  Amanda W. Dombrowski ,  Igor Dubovyk ,  Stephen N. Greszler ,  Dimitri Khrakovsky ,  Chih-Hung Lee ,  James N. Newton ,  Elizabeth L. Noey ,  Akinori Okano ,  Kevin B. Sippy ,  Andrew J. Souers ,  Longcheng Wang ,  Noel S. Wilson ,  Jeffery A. Zablocki

IPC: C07D471/04 ,  C07D519/00 ,  C07D487/04

Abstract: The present invention provides for compounds of formula (I) wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.

公开(公告)号：US20240109877A1

公开(公告)日：2024-04-04

申请号：US18187489

申请日：2023-03-21

Applicant: AbbVie Inc.

Inventor： Zhiguo Bian ,  Jason P. Burke ,  Zhaozhong J. Jia ,  Xingyu Jiang ,  Matthew H. Katcher ,  Venkat Reddy Mali ,  Violeta L. Marin ,  Elizabeth L. Noey ,  Akinori Okano ,  Alexey A. Rivkin ,  Spencer O. Scholz ,  Kevin R. Woller ,  Xianrui Zhao ,  Ashley M. Adams ,  Berenger Biannic ,  Shahab Mortezaei ,  Joshua N. Payette ,  Jeffery A. Zablocki

IPC: C07D413/14 ,  A61P35/02

CPC classification number: C07D413/14 ,  A61P35/02

Abstract: The present invention provides for compounds of formula (I)




wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.